QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Evolus, Inc. (EOLS)

Healthcare

No action
Fundamental
2
Sentiment
3
Technical
3

Do Nothing: fundamentalScore 2 is below the required floor of 3, so no bullish entry can be emitted regardless of chart quality; independently neither entry type qualifies — a pullback limit would be countertrend (price 7.4967 below SMA50 7.6657 with MACD line -0.12), and a breakout buy-stop above 7.55 prices an R/R of 0.78 against the 6.55 structural stop, under the 1.0 floor.

Analysis as of 2026-11-12· more than 2 trading days ago

Company overview

Evolus, Inc. provides medical aesthetic solutions in the U.S., focusing on healthcare professionals and their patients. Its key product, Jeuveau, is a botulinum toxin type A formulation for reducing frown lines in adults. Founded in 2012, the company is headquartered in Newport Beach, California.

Fundamental

weak
Fundamental2
Elevated risk

Evolus shows improving operations but remains unprofitable with a leveraged balance sheet and single-product risk.

Evolus is growing double digits at a roughly 66% gross margin and has cut its cash burn sharply, but it is still unprofitable, carries a stockholders' deficit and $165.6 million of debt against $41.7 million of cash, and faces single-product, single-supplier, tariff and settlement-compliance risk. A speculative turnaround with elevated risk — not yet an investable quality story.

Sentiment

fair
Sentiment3
Mixed / forming

Sentiment improved post-Q3 earnings, but regulatory and insider selling concerns persist.

Dominant driver is the Q3 2026 print (2026-11-04, announced) — revenue +13% to $78.0M, a fourth consecutive positive adjusted-EBITDA quarter, reaffirmed FY2026 guidance with a lowered non-GAAP opex outlook, and a same-week price-target raise to $15.40 — producing a determinate positive sentiment delta (baseline -0.13 → scoring +0.18, ~+0.31) as the October FDA-warning-letter coverage aged out of the window. The Red-Flag Screen is clean with no severe or moderate flag fired and no cap applied, but the setup is held below the top band because the rewarded catalyst is trailing and only partially priced, an EPS miss inside the same print offsets the revenue beat, and no forward-dated driver sits inside the next 30 days.

Technical

fair
Technical3
Mixed / recovering

The stock has reclaimed some moving averages but remains below key resistance levels, indicating a neutral trend.

EOLS is a recovering chart, not a confirmed uptrend. At 7.4967 the stock has reclaimed its SMA20 (7.25), EMA9 (7.21), EMA21 (7.30), SMA200 (6.36) and the daily VWAP (7.44) after the 2026-11-10 flush to 6.63, but it remains below the SMA50 (7.67) and the MACD line (-0.12) is still under zero even though the histogram has just flipped positive (+0.03). RSI14 52.5 and ADX14 14.6 describe a neutral, trendless tape, and the 2026-11-11 session (+8.01% on 1.29M shares) is the only genuine accumulation print in the recent window. Chart quality is mixed — four constructive confirmations (short-stack reclaim, MACD histogram cross, Williams %R off oversold at -23.47, price above VWAP) against two material negatives (SMA50 overhead at 7.67, MACD line below zero) — so technicalScore 3. The trade itself is blocked by the fundamental floor (fundamentalScore 2 < 3), so the chart read is preserved while the action goes to Do Nothing.

You’re looking at 2026-11-12 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.